Intravaginal lactic acid gel versus oral metronidazole for treating women with recurrent bacterial vaginosis: the VITA randomised controlled trial

Table 3 Participant reported resolution of bacterial vaginosis at Week 2 – between group comparison^a

Resolution of bacterial vaginosis at Week 2	Oral metronidazole (n = 259)	Intravaginal lactic acid gel (n = 259)	Adjusted risk difference^a (95% CI)	Adjusted risk ratio^b (95% CI)	Adjusted odds ratio^b (95% CI)
Yes	143 (70%)	97 (47%)	-23.2% (-32.3, -14.0)%	0.67 (0.57, 0.79)	0.38 (0.25, 0.57)
No	61 (30%)	108 (53%)
Missing	55	54

CI confidence interval
All data are n (%) unless otherwise indicated
^aDifference is lactic acid minus metronidazole, and ratios are lactic acid/metronidazole
^bAdjusted for: site, number of bacterial vaginosis episodes in 12 months before baseline (0, 1–3, > 3), female partner in 12 months before baseline (yes/no). Vaginal douching was not included as a covariate as it was omitted from the output due to a dependency between the independent variables

ISSN: 1472-6874